Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chinese Academy of Medical Sciences & Peking Union Medical College STAT3 compound L20: sourced facts only. name: "Mechanistic investigations confirmed that L20 directly binds to STAT3 protein (KD = 6.16 μM), specifically interacting with its SH2 domain." [PMID:41564506]; target: "Mechanistic investigations confirmed that L20 directly binds to STAT3 protein (KD = 6.16 μM), specifically interacting with its SH2 domain." [PMID:41564506]; developer: "State Key Laboratory of Digestive Health, Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China." [PMID:41564506]; stage: "Notably, in a murine MC38 subcutaneous xenograft model, L20 administration (20 mg/kg, i.p.) significantly suppressed tumor growth, achieving a tumor growth inhibition rate of 59.8 %." [PMID:41564506]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chinese Academy of Medical Sciences & Peking Union Medical College STAT3 compound L20.